| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/14/2003 | US6506596 Generating apoptotic bodies of somatic donor cells, incubating to allow for integration of DNA of the bodies into engulfing recipient cells |
| 01/14/2003 | US6506587 Nucleotide sequences coding enzymatic polypeptide; for use as an antitumor a gents |
| 01/14/2003 | US6506581 Nucleotide sequence of the Haemophilus influenzae Rd genome, fragments thereof, and uses thereof |
| 01/14/2003 | US6506580 Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening |
| 01/14/2003 | US6506386 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent |
| 01/14/2003 | US6506385 Administering interferon, such as type I, to birds in ovo during last quarter of incubation; newcastle disease |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/14/2003 | US6506362 Peptides and peptide mimetics attached to labels and/or hydrophilic polymmers; treating hematological disorders, particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions |
| 01/14/2003 | CA2194444C Immunomodulators |
| 01/14/2003 | CA2086922C Synthetic peptides and mixtures thereof for detecting hiv antibodies |
| 01/09/2003 | WO2003003016A1 Diagnostic methods and agents |
| 01/09/2003 | WO2003002745A2 The cage gene of actinobacillus actinomycetemcomitans, the protein it encodes and uses thereof |
| 01/09/2003 | WO2003002734A1 Anticomplement polypeptide from salivary glands of the tick ixodes ricinus |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002607A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 01/09/2003 | WO2003002602A2 Nogo and nogo receptor derived peptides for t-cell mediated neuroprotection |
| 01/09/2003 | WO2003002600A1 Use of soluble cytokeratine-1-fragments in diagnostics and therapy |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002144A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | WO2003002143A1 A novel engineered superantigen for human therapy |
| 01/09/2003 | WO2003002142A1 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002069A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | WO2003002068A2 Diagnosis and treatment of cancer |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003001981A2 Method of promoting engraftment of a donor transplant in a recipient host |
| 01/09/2003 | WO2002092825A3 Retroviral vectors for gene therapy |
| 01/09/2003 | WO2002087612A3 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/09/2003 | WO2002077195A9 Plasmodium falciparum ama-1 protein and uses thereof |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002058725A3 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002038769A3 Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
| 01/09/2003 | WO2002036625A3 Prokineticin polypeptides, related compositions and methods |
| 01/09/2003 | WO2002036097A3 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/09/2003 | WO2002032946A8 Basb207 polypeptides and polynucleotides from nontypeable haemophilus influenzae |
| 01/09/2003 | WO2002032943A3 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 01/09/2003 | WO2002020041A3 Eia vaccine and diagnostic |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002013855A3 Vaccines containing ribavirin and methods of use thereof |
| 01/09/2003 | WO2002011756A3 Anti-plasmodium compositions and methods of use |
| 01/09/2003 | WO2002002605A3 Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001070776A3 Nimr compositions and their methods of use |
| 01/09/2003 | WO2001068134A9 Therapies that improve graft survival, using antibodies against a b7 antigen |
| 01/09/2003 | US20030009025 For vaccination against botulism |
| 01/09/2003 | US20030009019 Novel telomerase |
| 01/09/2003 | US20030009010 As vaccines for therapy and prophylaxis of Haemophilus influenzae infection |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008875 Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system |
| 01/09/2003 | US20030008864 Treatment of diseases involving cyst formation |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008839 Use of a dimethyldialkylammonium salt as an adjuvant for a nucleic acid vaccine |
| 01/09/2003 | US20030008836 Eukaryotic gene expression cassette and uses thereof |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008813 Intracellular protein delivery compositions and methods of use |
| 01/09/2003 | US20030008391 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008376 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008357 Polypeptide for use in the treatment of inflammation, rheumatoid arritis, psoriasis, and diabetic retinopathy |
| 01/09/2003 | US20030008342 Vaccine for use in the treatment and prevention of cancer, autoimmune disease, human viral infections |
| 01/09/2003 | US20030008330 Nucleotide sequences coding polypeptides for use in the treatment and prevention of cancer and autoimmune disease |
| 01/09/2003 | US20030008299 Nucleotide sequences coding polypeptides for use in the treatment of cancer |
| 01/09/2003 | US20030008279 Cells for use in the diagnosis and treatment of viral diseases |
| 01/09/2003 | US20030008274 Nucleotide sequences coding polypeptide for use in the treatment of and prevention of viral diseases |
| 01/09/2003 | US20030007981 Vaccine, diagnosis of infection |
| 01/09/2003 | US20030007980 Urease-based vaccine and treatment for helicobacter infection |
| 01/09/2003 | US20030007979 Intranasal administering |
| 01/09/2003 | US20030007978 Quantiative analysis; genetic engineering |
| 01/09/2003 | US20030007977 Vaccine containing amino acid |
| 01/09/2003 | US20030007976 Anticancer agents; sensitivity to Mycobacterium |
| 01/09/2003 | US20030007969 Administering integrin antagonist |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007967 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality |
| 01/09/2003 | CA2452202A1 Diagnostic methods and agents |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | CA2452058A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | CA2451955A1 Antibodies to opgl |
| 01/09/2003 | CA2451846A1 Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
| 01/09/2003 | CA2451816A1 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | CA2451739A1 Hcv e1e2 vaccine compositions |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451218A1 Diagnosis and treatment of cancer |
| 01/08/2003 | EP1273918A2 Method of selecting evolved binding members using a native epitope |
| 01/08/2003 | EP1273660A2 Human sodium-hydrogen exchanger like protein 1 |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272665A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/08/2003 | EP1272652A2 Herpes viruses for immune modulation |
| 01/08/2003 | EP1272647A1 Multivalent antibodies and uses therefor |
| 01/08/2003 | EP1272636A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 01/08/2003 | EP1272635A1 Cryptic-like secreted protein |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272633A2 Compositions and methods for dendritic cell-based immunotherapy |
| 01/08/2003 | EP1272617A2 Prostate cell lines and their use |
| 01/08/2003 | EP1272527A2 Anti-d monoclonal antibodies |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272523A1 Human emr2, a g-protein coupled receptor from the egf-tm7 family |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |